KR20060124646A - 1-아칸-2-올 치환된 피페라진 및 피페리딘 화합물 - Google Patents

1-아칸-2-올 치환된 피페라진 및 피페리딘 화합물 Download PDF

Info

Publication number
KR20060124646A
KR20060124646A KR1020067011920A KR20067011920A KR20060124646A KR 20060124646 A KR20060124646 A KR 20060124646A KR 1020067011920 A KR1020067011920 A KR 1020067011920A KR 20067011920 A KR20067011920 A KR 20067011920A KR 20060124646 A KR20060124646 A KR 20060124646A
Authority
KR
South Korea
Prior art keywords
yloxy
methylbenzothiazol
piperazinyl
propyl
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020067011920A
Other languages
English (en)
Korean (ko)
Inventor
엘파티 엘제인
프라바 이브라힘
벤카타 팔레
케니스 레더
제프리 에이 자블록키
Original Assignee
씨브이 쎄러퓨틱스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 씨브이 쎄러퓨틱스, 인코포레이티드 filed Critical 씨브이 쎄러퓨틱스, 인코포레이티드
Publication of KR20060124646A publication Critical patent/KR20060124646A/ko
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56Nitrogen atoms
    • C07D211/58Nitrogen atoms attached in position 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62Benzothiazoles
    • C07D277/64Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020067011920A 2003-12-18 2004-12-17 1-아칸-2-올 치환된 피페라진 및 피페리딘 화합물 Ceased KR20060124646A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53125303P 2003-12-18 2003-12-18
US60/531,253 2003-12-18

Publications (1)

Publication Number Publication Date
KR20060124646A true KR20060124646A (ko) 2006-12-05

Family

ID=34710215

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020067011920A Ceased KR20060124646A (ko) 2003-12-18 2004-12-17 1-아칸-2-올 치환된 피페라진 및 피페리딘 화합물

Country Status (7)

Country Link
US (4) US7115610B2 (https=)
EP (1) EP1723129A1 (https=)
JP (1) JP2007514769A (https=)
KR (1) KR20060124646A (https=)
AU (1) AU2004303882A1 (https=)
CA (1) CA2550257A1 (https=)
WO (1) WO2005061470A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1723129A1 (en) * 2003-12-18 2006-11-22 Cv Therapeutics, Inc. 1-akan-2-ol substituted piperazine and piperidine compounds
EP1829866A1 (en) * 2006-03-02 2007-09-05 Laboratorios Del Dr. Esteve, S.A. Sigma receptor inhibitors
KR20110022620A (ko) 2008-05-30 2011-03-07 다케다 야쿠힌 고교 가부시키가이샤 복소환 화합물
CN105175401A (zh) * 2015-10-16 2015-12-23 北京康立生医药技术开发有限公司 一种依匹哌唑的制备方法
EP4334293A1 (en) * 2021-05-07 2024-03-13 Merck Sharp & Dohme LLC Cycloalkyl 3-oxopiperazine carboxamides and cycloheteroalkyl 3-oxopiperazine carboxamides as nav1.8 inhibitors

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2034305B (en) * 1978-10-24 1982-12-22 Wyeth John & Brother Ltd Preparation of piperidine derivatives
DE3118881A1 (de) 1980-09-29 1982-06-24 Oltmanns Ziegel Und Kunststoffe Gmbh, 2905 Edewecht "ziegel"
US4766125A (en) 1981-06-23 1988-08-23 Janssen Pharmaceutica N.V. N-aryl-piperazinealkanamides useful for protecting hearts from myocardial injury caused by ischaemia, anoxia or hypoxia
US4558129A (en) 1983-05-18 1985-12-10 Syntex (U.S.A.) Inc. Benzodioxanyl-hydroxyethylene-piperazinyl acetanilides which effect calcium entry and β-blockade
US4567264A (en) 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
ATE142497T1 (de) 1989-06-23 1996-09-15 Syntex Inc Ranolazin und verwandte piperazine zur behandlung von geweben, von physischen oder chemischen schäden betroffen
HU209723B (en) * 1990-10-31 1994-10-28 Richter Gedeon Vegyeszet Process for producing of piperazine derivatives
US5455045A (en) 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
JP2004505886A (ja) * 2000-02-18 2004-02-26 スィーヴィー セラピューティクス インコーポレイテッド 鬱血性心不全の処置における部分的な脂肪酸酸化阻害剤
AU2001238590A1 (en) 2000-02-22 2001-09-03 Cv Therapeutics, Inc. Substituted piperazine compounds
US6451798B2 (en) 2000-02-22 2002-09-17 Cv Therapeutics, Inc. Substituted alkyl piperazine derivatives
US6677336B2 (en) 2000-02-22 2004-01-13 Cv Therapeutics, Inc. Substituted piperazine compounds
US6552023B2 (en) 2000-02-22 2003-04-22 Cv Therapeutics, Inc. Aralkyl substituted piperazine compounds
IL151178A0 (en) * 2000-02-22 2003-04-10 Cv Therapeutics Inc Substituted piperazine compounds
ES2267748T3 (es) * 2000-04-07 2007-03-16 Astrazeneca Ab Compuestos de quinazolina.
US6573264B1 (en) * 2000-10-23 2003-06-03 Cv Therapeutics, Inc. Heteroaryl alkyl piperazine derivatives
WO2003008411A1 (en) 2001-07-19 2003-01-30 Cv Therapeutics, Inc. Substituted piperazine compounds and their use as fatty acid oxidation inhibitors
US7001909B2 (en) 2001-07-19 2006-02-21 Cv Therapeutics, Inc. Substituted heterocyclic compounds
US6827946B2 (en) * 2001-12-05 2004-12-07 Collegium Pharmaceutical, Inc. Compositions containing both sedative and non-sedative antihistamines
US7144691B2 (en) * 2002-03-05 2006-12-05 Ciba Specialty Chemicals Corporation Color photographic recording material
US20030220344A1 (en) * 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias
EP1723129A1 (en) * 2003-12-18 2006-11-22 Cv Therapeutics, Inc. 1-akan-2-ol substituted piperazine and piperidine compounds

Also Published As

Publication number Publication date
US20090054457A1 (en) 2009-02-26
JP2007514769A (ja) 2007-06-07
US7452889B2 (en) 2008-11-18
US7262198B2 (en) 2007-08-28
AU2004303882A1 (en) 2005-07-07
US20060229317A1 (en) 2006-10-12
WO2005061470A1 (en) 2005-07-07
EP1723129A1 (en) 2006-11-22
US7115610B2 (en) 2006-10-03
US20050197346A1 (en) 2005-09-08
CA2550257A1 (en) 2005-07-07
US20080032993A1 (en) 2008-02-07

Similar Documents

Publication Publication Date Title
US7452889B2 (en) Substituted heterocyclic compounds
EP1567525B1 (en) Substituted piperazine compounds and their use as fatty acid oxidation inhibitors
EP1578737B1 (en) Substituted heterocyclic compounds
AU2004209522A1 (en) Substituted heterocyclic compounds useful in the treatment of cardiovascular diseases
EP1806346B1 (en) Substituted piperazine compounds and their use as fatty acid oxidation inhibitors
KR20060065586A (ko) 지방산 산화 저해제로서의, 피페라진 및 피페리딘의 우레아유도체
US7601721B2 (en) Substituted heterocyclic compounds
HK1083492B (en) Substituted piperazine compounds and their use as fatty acid oxidation inhibitors
HK1111683B (en) Substituted piperazine compounds and their use as fatty acid oxidation inhibitors
HK1085467B (en) Substituted heterocyclic compounds

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20060616

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20091214

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20110708

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20111222

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20110708

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I